Cart
sales@molnova.com
Home - Products - GPCR/G Protein - Glucagon Receptor - NNC 92-1687

NNC 92-1687

CAS No. 22903-37-3

NNC 92-1687( —— )

Catalog No. M34348 CAS No. 22903-37-3

NNC 92-1687 is a selective glucagon receptor antagonist that can be used to study type 2 diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 550 In Stock
5MG 834 In Stock
10MG 1121 In Stock
25MG 1501 In Stock
50MG 1841 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    NNC 92-1687
  • Note
    Research use only, not for human use.
  • Brief Description
    NNC 92-1687 is a selective glucagon receptor antagonist that can be used to study type 2 diabetes.
  • Description
    NNC 92-1687 is a selective glucagon receptor antagonist that can be used to study type 2 diabetes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    Glucagon Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    22903-37-3
  • Formula Weight
    300.33
  • Molecular Formula
    C15H12N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    S(CC(=O)C1=CC(O)=C(O)C=C1)C=2NC=3C(N2)=CC=CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Methylprodnisolone S...

    A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.

  • HAEGTFT

    HAEGTFT is the first N-terminal 1-7 residues of GLP-1 peptide.

  • des-His1-[Glu9]-Gluc...

    Glucagon receptor antagonist (pA2 = 7.2 for inhibition of glucagon-induced adenylyl cyclase activation in rat liver membranes); displays no agonist activity. Enhances glucose-stimulated pancreatic insulin release in vitro. Blocks added glucagon-induced hyperglycemia in normal rabbits without affecting glycogenolysis in vivo. Also blocks endogenous glucagon-induced hyperglycemia in streptozocin diabetic rats.

Sign In Join Free